公开(公告)号：US11225459B2

公开(公告)日：2022-01-18

申请号：US16637695

申请日：2018-08-09

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： Nadezhda German ,  Mikelis Constantinos

IPC: C07C275/30

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea compounds acts by blocking at targeted receptors in the brain that contribute to the increase in inflammation. Combinations of receptors, H1 receptor, H2 receptor, dopamine transporter (DAT), and/or 5HT3C receptor, are individually and/or collectively inhibited by the same compositions of the present disclosure, and this ability leads to a decrease in brain edema. The DAT inhibitory effects additionally maintains dopamine levels in a patient.

公开(公告)号：US20200181069A1

公开(公告)日：2020-06-11

申请号：US16637695

申请日：2018-08-09

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： Nadezhda German ,  Mikelis Constantinos

IPC: C07C275/30

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea compounds acts by blocking at targeted receptors in the brain that contribute to the increase in inflammation. Combinations of receptors, H1 receptor, H2 receptor, dopamine transporter (DAT), and/or 5HT3C receptor, are individually and/or collectively inhibited by the same compositions of the present disclosure, and this ability leads to a decrease in brain edema. The DAT inhibitory effects additionally maintains dopamine levels in a patient.